Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control

Resistance to paclitaxel chemotherapy frequently develops in ovarian cancer. Oncolytic adenoviruses are a novel therapy for human malignancies that are being evaluated in early phase trials. However, there are no reliable predictive biomarkers for oncolytic adenovirus activity in ovarian cancer. We...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Oncol
Autori principali: Ingemarsdotter, Carin K., Tookman, Laura A., Browne, Ashley, Pirlo, Katrina, Cutts, Rosalind, Chelela, Claude, Khurrum, Karisma F., Leung, Elaine Y.L., Dowson, Suzanne, Webber, Lee, Khan, Iftekhar, Ennis, Darren, Syed, Nelofer, Crook, Tim R., Brenton, James D., Lockley, Michelle, McNeish, Iain A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2014
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528770/
https://ncbi.nlm.nih.gov/pubmed/25560085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2014.12.007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi